, Volume 10, Issue 4, pp 193–198 | Cite as

Clathrin heavy chain is a useful immunohistochemical marker for esophageal squamous intraepithelial neoplasia

  • Kazuya Tokita
  • Masanori SeimiyaEmail author
  • Kazuyuki Matsushita
  • Takeshi Tomonaga
  • Kiyotaka Onodera
  • Syoji Ohki
  • Tohru Tanizawa
  • Masaya Uesato
  • Hideaki Shimada
  • Hisahiro Matsubara
  • Yukio Nakatani
  • Fumio Nomura
Original Article



Recent advances in the endoscopic diagnosis and treatment of esophageal cancer have facilitated the detection and treatment of minute tumors, necessitating the accurate histopathological diagnosis of early esophageal cancer or precancerous lesions. This study evaluated the usefulness of immunohistochemical analysis (IHC) of clathrin heavy chain (CHC) as a marker for early esophageal cancer.


The immunoreactivity of CHC was analyzed in 409 esophageal specimens using a tissue array. Immunoreactivities of CHC, p53, and Ki67 were then compared in 44 endoscopically resected specimens.


CHC expression was significantly stronger in the cytoplasm of esophageal squamous cell carcinomas compared with non-tumor specimens in the tissue array. CHC expression in endoscopic specimens was significantly stronger in the cytoplasm of high-grade intraepithelial neoplasias and superficial carcinomas than in benign squamous epithelium and low-grade intraepithelial neoplasias. The sensitivity and specificity of CHC for the diagnosis of esophageal lesions were 75 and 96 %, respectively. These accuracies were comparable with those of p53 (43 and 98 %) and Ki67 (68 and 100 %). In addition, the sensitivity was increased by using a combination of markers as follows: 80 %, CHC + p53; 78 %, CHC + Ki67; 90 %, CHC + p53 + Ki67.


CHC detected by IHC may be a useful marker for the pathological diagnosis of esophageal squamous intraepithelial neoplasia.


Clathrin heavy chain Endoscopy Esophageal cancer Immunohistochemistry Marker 



This study received financial support from a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (no. 22590518 and 25460675).

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard statement

The authors work conformed to the guidelines set forth in the Helsinki Declaration of 1975, as revised in 2000.


  1. 1.
    Lerut T, Coosemans W, De Leyn P, Van Raemdonck D, Deneffe G, Decker G. Treatment of esophageal carcinoma. Chest. 1999;116:463S–5S.PubMedCrossRefGoogle Scholar
  2. 2.
    Mroczko B, Kozlowski M, Groblewska M, Lukaszewicz M, Niklinski J, Jelski W, Laudanski J, Chyczewski L, Szmitkowski M. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta. 2008;389:61–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003;133:486–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.PubMedCrossRefGoogle Scholar
  5. 5.
    Shimada H, Yajima S, Oshima Y, Hiwasa T, Tagawa M, Matsushita K, Nomura F. Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus, Inpress.Google Scholar
  6. 6.
    Mori M, Adachi Y, Matsushima T, Matsuda H, Kuwano H, Sugimachi K. Lugol staining pattern and histology of esophageal lesions. Am J Gastroenterol. 1993;88:701–5.PubMedGoogle Scholar
  7. 7.
    Seimiya M, Tomonaga T, Matsushita K, Sunaga M, Oh-Ishi M, Kodera Y, Maeda T, Takano S, Togawa A, Yoshitomi H, Otsuka M, Yamamoto M, Nakano M, Miyazaki M, Nomura F. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and form imino transferase cyclo deaminase. Hepatology. 2008;48:519–30.PubMedCrossRefGoogle Scholar
  8. 8.
    Kirchhausen T. Clathrin. Annu Rev Biochem. 2000;69:699–727.PubMedCrossRefGoogle Scholar
  9. 9.
    Royle SJ, Lagnado L. Trimerisation is important for the function of clathrin at the mitotic spindle. J Cell Sci. 2006;119:4071–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Ohata H, Ota N, Shirouzu M, Yokoyama S, Yokota J, Taya Y, Enari M. Identification of a function-specific mutation of clathrin heavy chain (CHC) required for p53 transactivation. J Mol Biol. 2009;394:460–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Squamous cell carcinoma of the oesophagus. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System; 2000 pp. 11–19.Google Scholar
  12. 12.
    Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, Li JY, Blot WJ, Li B, Taylor PR. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. Cancer. 1994;74:1686–92.PubMedCrossRefGoogle Scholar
  13. 13.
    Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut. 2002;51:130–1.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang GQ, Abnet CC, Shen Q, Lewin KJ, Sun XD, Roth MJ, Qiao YL, Mark SD, Dong ZW, Taylor PR, Dawsey SM. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 2005;54:187–92.PubMedCrossRefGoogle Scholar
  16. 16.
    Shimizu M, Nagata K, Yamaguchi H, Kita H. Squamous intraepithelial neoplasia of the esophagus: past, present, and future. J Gastroenterol. 2009;44:103–12.PubMedCrossRefGoogle Scholar
  17. 17.
    Xu M, Jin YL, Fu J, Huang H, Chen SZ, Qu P, Tian HM, Liu ZY, Zhang W. The abnormal expression of retinoic acid receptor-beta, p 53 and Ki67 protein in normal, premalignant and malignant esophageal tissues. World J Gastroenterol. 2002;8:200–2.PubMedGoogle Scholar
  18. 18.
    Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988;8:531–9.PubMedGoogle Scholar
  19. 19.
    Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu SM, Kusters I, Resau JH, Trump BF, Lane DP, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res. 1992;52:6092–7.PubMedGoogle Scholar
  20. 20.
    Gao H, Wang LD, Zhou Q, Hong JY, Huang TY, Yang CS. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan. China. Cancer Res. 1994;54:4342–6.Google Scholar
  21. 21.
    Kobayashi M, Kawachi H, Takizawa T, Uchida K, Sekine M, Kumagai J, Momma K, Nemoto T, Akashi T, Funata N, Eishi Y, Koike M. p53 Mutation analysis of low-grade dysplasia and high-grade dysplasia/carcinoma in situ of the esophagus using laser capture microdissection. Oncology. 2006;71:237–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol. 1990;1:199–206.PubMedGoogle Scholar
  23. 23.
    Wang WC, Wu TT, Chandan VS, Lohse CM, Zhang L. Ki-67 and ProExC are useful immunohistochemical markers in esophageal squamous intraepithelial neoplasia. Hum Pathol. 2011;42:1430–7.PubMedCrossRefGoogle Scholar

Copyright information

© The Japan Esophageal Society and Springer Japan 2013

Authors and Affiliations

  • Kazuya Tokita
    • 1
    • 2
  • Masanori Seimiya
    • 2
    • 3
    Email author
  • Kazuyuki Matsushita
    • 2
    • 3
  • Takeshi Tomonaga
    • 4
  • Kiyotaka Onodera
    • 5
  • Syoji Ohki
    • 5
  • Tohru Tanizawa
    • 6
  • Masaya Uesato
    • 7
  • Hideaki Shimada
    • 8
  • Hisahiro Matsubara
    • 7
  • Yukio Nakatani
    • 5
    • 9
  • Fumio Nomura
    • 2
    • 3
  1. 1.Division of Laboratory MedicineNational Cancer Center Research InstituteTokyoJapan
  2. 2.Department of Molecular Diagnosis, Graduate School of MedicineChiba UniversityChibaJapan
  3. 3.Division of Laboratory MedicineChiba University HospitalChibaJapan
  4. 4.Laboratory of Proteome ResearchNational Institute of Biomedical InnovationOsakaJapan
  5. 5.Department of PathologyChiba University HospitalChibaJapan
  6. 6.Clinical LaboratoryTokyo Metropolitan Bokuto HospitalTokyoJapan
  7. 7.Department of Frontier Surgery, Graduate School of MedicineChiba UniversityChibaJapan
  8. 8.Department of SurgeryToho University School of MedicineTokyoJapan
  9. 9.Department of Diagnostic Pathology, Graduate School of MedicineChiba UniversityChibaJapan

Personalised recommendations